Clinical trials: Death, Cardiac
Electrocardiography
Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease
Patients with insulin-dependent diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an excessive risk for cardiac arrhythmias, in particular sudden cardiac death (SCD).
- Trial name
- HypoArrhyth (NCT02315300)
- Testing
- medilog® DARWIN FD12, Continuous Glucose Monitoring
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- RWTH Aachen University
Cardiomyopathies, Cardiac Death, Sudden
Same Day Subcutaneous ICD And Send Home (DASH)
Design: Prospective, non-randomized single center study at The Ohio State University Wexner Medical Center. Purpose: The purpose of this study is to prospectively evaluate a specific analgesia protocol designed to allow for same…
- Trial name
- DASH (NCT03504839)
- Testing
- Subcutaneous ICD with same day discharge
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Emile Daoud, MD
Heart Failure
Biomarkers for Prognosis of Ambulatory Chronic Heart Failure Patients
Biomarkers representing distinct biological domains including neurohormonal, inflammatory, metabolic-nutritional, oxidative-nitrosative and myocardial injury, might alone or in combination provide prognostic information on…
- Trial name
- NCT01113866
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- University of Parma
Cardiac Death, Cardiac Death, Sudden
Longitudinal Evaluation of Active-Duty Personnel with Accessory Pathways (LEAD-AP)
The investigators propose a secondary chart review using EMR data to identify risk factors for sudden cardiac death in active-duty members diagnosed with an accessory pathway between the ages of 18-40.
- Conditions
- Cardiac Death, Cardiac Death, Sudden, Wolf Parkinson White Syndrome
- Trial name
- LEAD-AP (NCT06798961)
- Testing
- Ablation, Standard of care without ablation
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- United States Naval Medical Center, San Diego
Epilepsy
Cardiac Arrhythmias in Dravet Syndrome
SUMMARY Rationale: People with Dravet Syndrome (DS), a rare epilepsy syndrome, have a high risk of Sudden Unexpected Death in Epilepsy (SUDEP).
- Trial name
- NCT02415686
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 59 people
- Sponsor
- Stichting Epilepsie Instellingen Nederland
Sudden Cardiac Arrest, Ventricular Arrythmia
Improve Sudden Cardiac Arrest Study
The purpose of this study is to demonstrate that primary prevention patients with one or more additional risk factors (1.5 prevention criteria: syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent…
- Trial name
- NCT02099721
- Testing
- ICD or CRT-D Device
- Where
- 93 sites in Argentina, Belarus and 14 more
- Volunteers
- 4,222 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Liver Transplantation, Kidney Transplantation
Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death.
- Trial name
- NCT01197573
- Testing
- rTPA Treatment, No TPA Treatment
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- The Cleveland Clinic
Sudden Cardiac Death, Heart Failure
Educational Videos to Address Racial Disparities in Implantable Cardioverter Defibrillator Therapy
VIVID is a prospective, multicenter, randomized clinical trial in African American patients that will to evaluate: (1) the effect of an educational video on knowledge of sudden cardiac death (SCD) and implantable cardioverter…
- Trial name
- VIVID (NCT02819973)
- Testing
- Educational Video1, Educational Video 2, Usual Care 3
- Where
- 14 sites in United States
- Volunteers
- 343 people
- Sponsor
- Duke University
Cardiovascular Mortality
Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis
Research proposal to evaluate the impact of different phosphate binders on the progression of cardiovascular calcification and QT dispersion in new haemodialysis patients.
- Trial name
- Independent (NCT00710788)
- Testing
- sevelamer phosphate-binders, Calcium Carbonate
- Where
- Italy
- Volunteers
- 360 people
- Sponsor
- Azienda Sanitaria ASL Avellino 2
Arrhythmias, Cardiac
Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic
Biorepository of blood and or tissue samples from patients presenting with cardiac arrhythmia syndromes.
- Trial name
- NCT00921986
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Cardiac Complications, Sudden Cardiac Arrest
The Study Aims to Investigate the Frequency and Clinical Characteristics of Out-of-hospital Cardiac Arrests (OHCA) Occurring in Poland in 2023. This Research Seeks to Provide a Comprehensive Analysis of OHCA Incidents Across the Country, Focusing on Their Prevalence and the Associated Clinical fe
1. Objective According to the 2021 European Resuscitation Council (ERC) Guidelines, sudden cardiac arrest is the third leading cause of death in Europe.
- Conditions
- Cardiac Complications, Sudden Cardiac Arrest, Cardiac Diseases, Cardiac Arrest (CA)
- Trial name
- OHCA_PL (NCT06948266)
- Where
- Poland
- Volunteers
- 100,000 people
- Sponsor
- Medical University of Gdansk
Hypotension, Postoperative Complications
Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery
Major adverse cardiovascular events (MACE) are a leading cause of serious complications and death following major noncardiac surgery.
- Conditions
- Hypotension, Postoperative Complications, Acute Coronary Syndrome, Heart Failure
- Trial name
- BBB (NCT02533128)
- Testing
- Liberal blood pressure management, Tight blood pressure management
- Where
- Switzerland
- Volunteers
- 458 people
- Sponsor
- Miodrag Filipovic, Prof. Dr. med.
Cardiovascular Events, MACE
Tezspire Cardiac Events PASS
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for…
- Trial name
- TRESPASS (NCT06951867)
- Testing
- Tezepelumab
- Where
- 4 sites in United States, Denmark and 2 more
- Volunteers
- 16,640 people
- Sponsor
- AstraZeneca
Left Ventricular Systolic Dysfunction, Congestive Heart Failure
SCD-HeFT 10 Year Follow-up
No clinical trial that has examined the role of implantable cardioverter defibrillator (ICD) therapy in the prevention of Sudden Cardiac Death (SCD) has provided outcome data for longer than a few years.
- Conditions
- Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
- Trial name
- SCD-HeFT10 Yr (NCT01058837)
- Where
- United States
- Volunteers
- 1,855 people
- Sponsor
- Seattle Institute for Cardiac Research
Cardiac Death, Myocardial Infarction
Leaders Free III: BioFreedom™ Clinical Trial
A study evaluating the safety and efficacy of the BioFreedom™ Biolimus A9™ coated Cobalt Chromium coronary stent system in patients at high risk of bleeding
- Conditions
- Cardiac Death, Myocardial Infarction, Stent Thrombosis, Bleeding
- Trial name
- NCT03118895
- Testing
- BioFreedom™ BA9™ drug-coated stent
- Where
- 2 sites in France, Switzerland
- Volunteers
- 404 people
- Sponsor
- Biosensors Europe SA
Dilated Cardiomyopathy, Primary Prevention of Sudden Cardiac Death
Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy
With the present study the investigators intend to identify the morphologic and electrophysiologic substrate markers of increased arrhythmic risk in patients with dilated cardiomyopathy undergoing implantation of a defibrillator…
- Conditions
- Dilated Cardiomyopathy, Primary Prevention of Sudden Cardiac Death, Implantable Cardioverter Defibrillator
- Trial name
- EMOSIDD (NCT01378572)
- Where
- 3 sites in United States, Italy
- Volunteers
- 200 people
- Sponsor
- Catholic University of the Sacred Heart
Myocardial Infarction, Ventricular Dysfunction
Vest Prevention of Early Sudden Death Trial and VEST Registry
This study explores the hypothesis that wearable defibrillators can impact mortality by reducing sudden death during the first three months after a heart attack in persons with high risk for life-threatening arrhythmias.
- Conditions
- Myocardial Infarction, Ventricular Dysfunction, Sudden Death, Ventricular Tachycardia
- Trial name
- VEST (NCT01446965)
- Testing
- wearable defibrillator
- Where
- 71 sites in United States, Germany and 1 more
- Volunteers
- 2,348 people
- Sponsor
- University of California, San Francisco
High Risk Pregnancy, Congenital Heart Disease
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome.
- Conditions
- High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta
- Trial name
- NCT03775954
- Testing
- Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Myocardial Infarction, Death
Relation Between NLR and IMR in STEMI Patients
The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker for atherosclerotic process and predictor for clinical outcomes in patients with various cardiovascular diseases.
- Trial name
- NCT02828137
- Volunteers
- 123 people
- Sponsor
- Inha University Hospital
Myocardial Infarction
OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction
Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD).
- Trial name
- OMEGA (NCT00251134)
- Testing
- Zodin (drug)
- Where
- 10 sites in Germany
- Volunteers
- 3,800 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung